The global market for Recombinant Hirudin was estimated to be worth US$ 1600 million in 2023 and is forecast to a readjusted size of US$ 2327.5 million by 2030 with a CAGR of 5.5% during the forecast period 2024-2030

Recombinant Hirudin - Market

Hirudin is the most potent natural inhibitor of thrombin. Unlike antithrombin, hirudin binds to and inhibits only the activity of thrombin, with a specific activity on fibrinogen. Therefore, hirudin prevents or dissolves the formation of clots and thrombi (i.e., it has a thrombolytic activity), and has therapeutic value in blood coagulation disorders, in the treatment of skin hematomas and of superficial varicose veins, either as an injectable or a topical application cream. In some aspects, hirudin has advantages over more commonly used anticoagulants and thrombolytics, such as heparin, as it does not interfere with the biological activity of other serum proteins, and can also act on complexed thrombin.

It is difficult to extract large amounts of hirudin from natural sources, so a method for producing and purifying this protein using recombinant biotechnology has been developed. This has led to the development and marketing of a number of hirudin-based anticoagulant pharmaceutical products. Several other direct thrombin inhibitors are derived chemically from hirudin.

Recombinant Hirudin is derived from yeast and the polypeptide chain contains 65 amino acids and its Mw is 6979.5 Dalton which is identical to natural Hirudin except for the substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. The Recombinant Hirudin is purified by proprietary chromatographic techniques.

The market drivers for Recombinant Hirudin are the increasing prevalence of thrombosis and tumor diseases, the growing demand for Recombinant Hirudin in the Asia Pacific and the Middle East & Africa regions, and the development of new products with improved features and performance.

The market constraints for Recombinant Hirudin are the high cost of Recombinant Hirudin compared to other anticoagulants, the limited availability and accessibility of Recombinant Hirudin in some regions, the need for regular monitoring and dosage adjustment of Recombinant Hirudin, and the risk of side effects and complications such as bleeding, allergic reactions, and antibody formation.

The market opportunities for Recombinant Hirudin are the increasing demand for Recombinant Hirudin among patients with heparin-induced thrombocytopenia (HIT), a condition where heparin causes low platelet count and increased risk of blood clots, the integration of Recombinant Hirudin with software and cloud-based platforms for better management and tracking of treatment outcomes, and the application of Recombinant Hirudin in new fields such as cosmetic surgery and dentistry.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Recombinant Hirudin, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Recombinant Hirudin by region & country, by Type, and by Application.

The Recombinant Hirudin market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Hirudin.

Market Segmentation

Scope of Recombinant Hirudin - Market Report

Report Metric	Details
Report Name	Recombinant Hirudin - Market
Forecasted market size in 2030	US$ 2327.5 million
CAGR	5.5%
Forecasted years	2024 - 2030
Segment by Type:	12000ATU/mg 16000ATU/mg
Segment by Application	Thrombosis Disease Tumor Disease
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Abbott, The Medicines Company, Teva Pharmaceutical, Pfizer, Pentapharm, PrimeGene, Aniara Diagnostica, Bioassay Technology Laboratory, Novus Biologicals, Merck KGaA
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Recombinant Hirudin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Recombinant Hirudin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Recombinant Hirudin in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Recombinant Hirudin - Market size in 2030?

Ans: The Recombinant Hirudin - Market size in 2030 will be US$ 2327.5 million.

Who are the main players in the Recombinant Hirudin - Market report?

Ans: The main players in the Recombinant Hirudin - Market are Abbott, The Medicines Company, Teva Pharmaceutical, Pfizer, Pentapharm, PrimeGene, Aniara Diagnostica, Bioassay Technology Laboratory, Novus Biologicals, Merck KGaA

What are the Application segmentation covered in the Recombinant Hirudin - Market report?

Ans: The Applications covered in the Recombinant Hirudin - Market report are Thrombosis Disease, Tumor Disease

What are the Type segmentation covered in the Recombinant Hirudin - Market report?

Ans: The Types covered in the Recombinant Hirudin - Market report are 12000ATU/mg, 16000ATU/mg

1 Market Overview

1.1 Recombinant Hirudin Product Introduction

1.2 Global Recombinant Hirudin Market Size Forecast

1.2.1 Global Recombinant Hirudin Sales Value (2019-2030)

1.2.2 Global Recombinant Hirudin Sales Volume (2019-2030)

1.2.3 Global Recombinant Hirudin Sales Price (2019-2030)

1.3 Recombinant Hirudin Market Trends & Drivers

1.3.1 Recombinant Hirudin Industry Trends

1.3.2 Recombinant Hirudin Market Drivers & Opportunity

1.3.3 Recombinant Hirudin Market Challenges

1.3.4 Recombinant Hirudin Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Recombinant Hirudin Players Revenue Ranking (2023)

2.2 Global Recombinant Hirudin Revenue by Company (2019-2024)

2.3 Global Recombinant Hirudin Players Sales Volume Ranking (2023)

2.4 Global Recombinant Hirudin Sales Volume by Company Players (2019-2024)

2.5 Global Recombinant Hirudin Average Price by Company (2019-2024)

2.6 Key Manufacturers Recombinant Hirudin Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Recombinant Hirudin Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Recombinant Hirudin

2.9 Recombinant Hirudin Market Competitive Analysis

2.9.1 Recombinant Hirudin Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Recombinant Hirudin Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Hirudin as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 12000ATU/mg

3.1.2 16000ATU/mg

3.2 Global Recombinant Hirudin Sales Value by Type

3.2.1 Global Recombinant Hirudin Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Recombinant Hirudin Sales Value, by Type (2019-2030)

3.2.3 Global Recombinant Hirudin Sales Value, by Type (%) (2019-2030)

3.3 Global Recombinant Hirudin Sales Volume by Type

3.3.1 Global Recombinant Hirudin Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Recombinant Hirudin Sales Volume, by Type (2019-2030)

3.3.3 Global Recombinant Hirudin Sales Volume, by Type (%) (2019-2030)

3.4 Global Recombinant Hirudin Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Thrombosis Disease

4.1.2 Tumor Disease

4.2 Global Recombinant Hirudin Sales Value by Application

4.2.1 Global Recombinant Hirudin Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Recombinant Hirudin Sales Value, by Application (2019-2030)

4.2.3 Global Recombinant Hirudin Sales Value, by Application (%) (2019-2030)

4.3 Global Recombinant Hirudin Sales Volume by Application

4.3.1 Global Recombinant Hirudin Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Recombinant Hirudin Sales Volume, by Application (2019-2030)

4.3.3 Global Recombinant Hirudin Sales Volume, by Application (%) (2019-2030)

4.4 Global Recombinant Hirudin Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Recombinant Hirudin Sales Value by Region

5.1.1 Global Recombinant Hirudin Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Recombinant Hirudin Sales Value by Region (2019-2024)

5.1.3 Global Recombinant Hirudin Sales Value by Region (2025-2030)

5.1.4 Global Recombinant Hirudin Sales Value by Region (%), (2019-2030)

5.2 Global Recombinant Hirudin Sales Volume by Region

5.2.1 Global Recombinant Hirudin Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Recombinant Hirudin Sales Volume by Region (2019-2024)

5.2.3 Global Recombinant Hirudin Sales Volume by Region (2025-2030)

5.2.4 Global Recombinant Hirudin Sales Volume by Region (%), (2019-2030)

5.3 Global Recombinant Hirudin Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Recombinant Hirudin Sales Value, 2019-2030

5.4.2 North America Recombinant Hirudin Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Recombinant Hirudin Sales Value, 2019-2030

5.5.2 Europe Recombinant Hirudin Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Recombinant Hirudin Sales Value, 2019-2030

5.6.2 Asia Pacific Recombinant Hirudin Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Recombinant Hirudin Sales Value, 2019-2030

5.7.2 South America Recombinant Hirudin Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Recombinant Hirudin Sales Value, 2019-2030

5.8.2 Middle East & Africa Recombinant Hirudin Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Recombinant Hirudin Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Recombinant Hirudin Sales Value

6.2.1 Key Countries/Regions Recombinant Hirudin Sales Value, 2019-2030

6.2.2 Key Countries/Regions Recombinant Hirudin Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Recombinant Hirudin Sales Value, 2019-2030

6.3.2 United States Recombinant Hirudin Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Recombinant Hirudin Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Recombinant Hirudin Sales Value, 2019-2030

6.4.2 Europe Recombinant Hirudin Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Recombinant Hirudin Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Recombinant Hirudin Sales Value, 2019-2030

6.5.2 China Recombinant Hirudin Sales Value by Type (%), 2023 VS 2030

6.5.3 China Recombinant Hirudin Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Recombinant Hirudin Sales Value, 2019-2030

6.6.2 Japan Recombinant Hirudin Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Recombinant Hirudin Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Recombinant Hirudin Sales Value, 2019-2030

6.7.2 South Korea Recombinant Hirudin Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Recombinant Hirudin Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Recombinant Hirudin Sales Value, 2019-2030

6.8.2 Southeast Asia Recombinant Hirudin Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Recombinant Hirudin Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Recombinant Hirudin Sales Value, 2019-2030

6.9.2 India Recombinant Hirudin Sales Value by Type (%), 2023 VS 2030

6.9.3 India Recombinant Hirudin Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Abbott

7.1.1 Abbott Company Information

7.1.2 Abbott Introduction and Business Overview

7.1.3 Abbott Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

7.1.4 Abbott Recombinant Hirudin Product Offerings

7.1.5 Abbott Recent Development

7.2 The Medicines Company

7.2.1 The Medicines Company Company Information

7.2.2 The Medicines Company Introduction and Business Overview

7.2.3 The Medicines Company Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

7.2.4 The Medicines Company Recombinant Hirudin Product Offerings

7.2.5 The Medicines Company Recent Development

7.3 Teva Pharmaceutical

7.3.1 Teva Pharmaceutical Company Information

7.3.2 Teva Pharmaceutical Introduction and Business Overview

7.3.3 Teva Pharmaceutical Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Teva Pharmaceutical Recombinant Hirudin Product Offerings

7.3.5 Teva Pharmaceutical Recent Development

7.4 Pfizer

7.4.1 Pfizer Company Information

7.4.2 Pfizer Introduction and Business Overview

7.4.3 Pfizer Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Pfizer Recombinant Hirudin Product Offerings

7.4.5 Pfizer Recent Development

7.5 Pentapharm

7.5.1 Pentapharm Company Information

7.5.2 Pentapharm Introduction and Business Overview

7.5.3 Pentapharm Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

7.5.4 Pentapharm Recombinant Hirudin Product Offerings

7.5.5 Pentapharm Recent Development

7.6 PrimeGene

7.6.1 PrimeGene Company Information

7.6.2 PrimeGene Introduction and Business Overview

7.6.3 PrimeGene Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

7.6.4 PrimeGene Recombinant Hirudin Product Offerings

7.6.5 PrimeGene Recent Development

7.7 Aniara Diagnostica

7.7.1 Aniara Diagnostica Company Information

7.7.2 Aniara Diagnostica Introduction and Business Overview

7.7.3 Aniara Diagnostica Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

7.7.4 Aniara Diagnostica Recombinant Hirudin Product Offerings

7.7.5 Aniara Diagnostica Recent Development

7.8 Bioassay Technology Laboratory

7.8.1 Bioassay Technology Laboratory Company Information

7.8.2 Bioassay Technology Laboratory Introduction and Business Overview

7.8.3 Bioassay Technology Laboratory Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

7.8.4 Bioassay Technology Laboratory Recombinant Hirudin Product Offerings

7.8.5 Bioassay Technology Laboratory Recent Development

7.9 Novus Biologicals

7.9.1 Novus Biologicals Company Information

7.9.2 Novus Biologicals Introduction and Business Overview

7.9.3 Novus Biologicals Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

7.9.4 Novus Biologicals Recombinant Hirudin Product Offerings

7.9.5 Novus Biologicals Recent Development

7.10 Merck KGaA

7.10.1 Merck KGaA Company Information

7.10.2 Merck KGaA Introduction and Business Overview

7.10.3 Merck KGaA Recombinant Hirudin Sales, Revenue and Gross Margin (2019-2024)

7.10.4 Merck KGaA Recombinant Hirudin Product Offerings

7.10.5 Merck KGaA Recent Development

8 Industry Chain Analysis

8.1 Recombinant Hirudin Industrial Chain

8.2 Recombinant Hirudin Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Recombinant Hirudin Sales Model

8.5.2 Sales Channel

8.5.3 Recombinant Hirudin Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Abbott

The Medicines Company

Teva Pharmaceutical

Pfizer Inc

Pentapharm

Bioassay Technology Laboratory

List of Tables

Table 1. Recombinant Hirudin Market Trends

Table 2. Recombinant Hirudin Market Drivers & Opportunity

Table 3. Recombinant Hirudin Market Challenges

Table 4. Recombinant Hirudin Market Restraints

Table 5. Global Recombinant Hirudin Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Recombinant Hirudin Revenue Market Share by Company (2019-2024)

Table 7. Global Recombinant Hirudin Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global Recombinant Hirudin Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Recombinant Hirudin Price by Company (2019-2024) & (US$/Unit)

Table 10. Key Manufacturers Recombinant Hirudin Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Recombinant Hirudin Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Recombinant Hirudin

Table 13. Global Recombinant Hirudin Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Hirudin as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Recombinant Hirudin Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Recombinant Hirudin Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Recombinant Hirudin Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Recombinant Hirudin Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Recombinant Hirudin Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Recombinant Hirudin Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global Recombinant Hirudin Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global Recombinant Hirudin Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global Recombinant Hirudin Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Recombinant Hirudin Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Recombinant Hirudin Price by Type (2019-2024) & (US$/Unit)

Table 27. Global Recombinant Hirudin Price by Type (2025-2030) & (US$/Unit)

Table 28. Global Recombinant Hirudin Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Recombinant Hirudin Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Recombinant Hirudin Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Recombinant Hirudin Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Recombinant Hirudin Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Recombinant Hirudin Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global Recombinant Hirudin Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global Recombinant Hirudin Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global Recombinant Hirudin Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Recombinant Hirudin Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Recombinant Hirudin Price by Application (2019-2024) & (US$/Unit)

Table 39. Global Recombinant Hirudin Price by Application (2025-2030) & (US$/Unit)

Table 40. Global Recombinant Hirudin Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Recombinant Hirudin Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Recombinant Hirudin Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Recombinant Hirudin Sales Value by Region (2019-2024) & (%)

Table 44. Global Recombinant Hirudin Sales Value by Region (2025-2030) & (%)

Table 45. Global Recombinant Hirudin Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global Recombinant Hirudin Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global Recombinant Hirudin Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global Recombinant Hirudin Sales Volume by Region (2019-2024) & (%)

Table 49. Global Recombinant Hirudin Sales Volume by Region (2025-2030) & (%)

Table 50. Global Recombinant Hirudin Average Price by Region (2019-2024) & (US$/Unit)

Table 51. Global Recombinant Hirudin Average Price by Region (2025-2030) & (US$/Unit)

Table 52. Key Countries/Regions Recombinant Hirudin Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Recombinant Hirudin Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Recombinant Hirudin Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Recombinant Hirudin Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions Recombinant Hirudin Sales Volume, (2025-2030) & (K Units)

Table 57. Abbott Company Information

Table 58. Abbott Introduction and Business Overview

Table 59. Abbott Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 60. Abbott Recombinant Hirudin Product Offerings

Table 61. Abbott Recent Development

Table 62. The Medicines Company Company Information

Table 63. The Medicines Company Introduction and Business Overview

Table 64. The Medicines Company Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 65. The Medicines Company Recombinant Hirudin Product Offerings

Table 66. The Medicines Company Recent Development

Table 67. Teva Pharmaceutical Company Information

Table 68. Teva Pharmaceutical Introduction and Business Overview

Table 69. Teva Pharmaceutical Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 70. Teva Pharmaceutical Recombinant Hirudin Product Offerings

Table 71. Teva Pharmaceutical Recent Development

Table 72. Pfizer Company Information

Table 73. Pfizer Introduction and Business Overview

Table 74. Pfizer Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 75. Pfizer Recombinant Hirudin Product Offerings

Table 76. Pfizer Recent Development

Table 77. Pentapharm Company Information

Table 78. Pentapharm Introduction and Business Overview

Table 79. Pentapharm Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 80. Pentapharm Recombinant Hirudin Product Offerings

Table 81. Pentapharm Recent Development

Table 82. PrimeGene Company Information

Table 83. PrimeGene Introduction and Business Overview

Table 84. PrimeGene Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 85. PrimeGene Recombinant Hirudin Product Offerings

Table 86. PrimeGene Recent Development

Table 87. Aniara Diagnostica Company Information

Table 88. Aniara Diagnostica Introduction and Business Overview

Table 89. Aniara Diagnostica Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 90. Aniara Diagnostica Recombinant Hirudin Product Offerings

Table 91. Aniara Diagnostica Recent Development

Table 92. Bioassay Technology Laboratory Company Information

Table 93. Bioassay Technology Laboratory Introduction and Business Overview

Table 94. Bioassay Technology Laboratory Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 95. Bioassay Technology Laboratory Recombinant Hirudin Product Offerings

Table 96. Bioassay Technology Laboratory Recent Development

Table 97. Novus Biologicals Company Information

Table 98. Novus Biologicals Introduction and Business Overview

Table 99. Novus Biologicals Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 100. Novus Biologicals Recombinant Hirudin Product Offerings

Table 101. Novus Biologicals Recent Development

Table 102. Merck KGaA Company Information

Table 103. Merck KGaA Introduction and Business Overview

Table 104. Merck KGaA Recombinant Hirudin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 105. Merck KGaA Recombinant Hirudin Product Offerings

Table 106. Merck KGaA Recent Development

Table 107. Key Raw Materials Lists

Table 108. Raw Materials Key Suppliers Lists

Table 109. Recombinant Hirudin Downstream Customers

Table 110. Recombinant Hirudin Distributors List

Table 111. Research Programs/Design for This Report

Table 112. Key Data Information from Secondary Sources

Table 113. Key Data Information from Primary Sources

List of Figures

Figure 1. Recombinant Hirudin Product Picture

Figure 2. Global Recombinant Hirudin Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Recombinant Hirudin Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Recombinant Hirudin Sales Volume (2019-2030) & (K Units)

Figure 5. Global Recombinant Hirudin Sales Price (2019-2030) & (US$/Unit)

Figure 6. Recombinant Hirudin Report Years Considered

Figure 7. Global Recombinant Hirudin Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Recombinant Hirudin Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Recombinant Hirudin Revenue in 2023

Figure 10. Recombinant Hirudin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. 12000ATU/mg Picture

Figure 12. 16000ATU/mg Picture

Figure 13. Global Recombinant Hirudin Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Recombinant Hirudin Sales Value Market Share by Type, 2023 & 2030

Figure 15. Global Recombinant Hirudin Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 16. Global Recombinant Hirudin Sales Volume Market Share by Type, 2023 & 2030

Figure 17. Global Recombinant Hirudin Price by Type (2019-2030) & (US$/Unit)

Figure 18. Product Picture of Thrombosis Disease

Figure 19. Product Picture of Tumor Disease

Figure 20. Global Recombinant Hirudin Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 21. Global Recombinant Hirudin Sales Value Market Share by Application, 2023 & 2030

Figure 22. Global Recombinant Hirudin Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 23. Global Recombinant Hirudin Sales Volume Market Share by Application, 2023 & 2030

Figure 24. Global Recombinant Hirudin Price by Application (2019-2030) & (US$/Unit)

Figure 25. North America Recombinant Hirudin Sales Value (2019-2030) & (US$ Million)

Figure 26. North America Recombinant Hirudin Sales Value by Country (%), 2023 VS 2030

Figure 27. Europe Recombinant Hirudin Sales Value (2019-2030) & (US$ Million)

Figure 28. Europe Recombinant Hirudin Sales Value by Country (%), 2023 VS 2030

Figure 29. Asia Pacific Recombinant Hirudin Sales Value (2019-2030) & (US$ Million)

Figure 30. Asia Pacific Recombinant Hirudin Sales Value by Country (%), 2023 VS 2030

Figure 31. South America Recombinant Hirudin Sales Value (2019-2030) & (US$ Million)

Figure 32. South America Recombinant Hirudin Sales Value by Country (%), 2023 VS 2030

Figure 33. Middle East & Africa Recombinant Hirudin Sales Value (2019-2030) & (US$ Million)

Figure 34. Middle East & Africa Recombinant Hirudin Sales Value by Country (%), 2023 VS 2030

Figure 35. Key Countries/Regions Recombinant Hirudin Sales Value (%), (2019-2030)

Figure 36. Key Countries/Regions Recombinant Hirudin Sales Volume (%), (2019-2030)

Figure 37. United States Recombinant Hirudin Sales Value, (2019-2030) & (US$ Million)

Figure 38. United States Recombinant Hirudin Sales Value by Type (%), 2023 VS 2030

Figure 39. United States Recombinant Hirudin Sales Value by Application (%), 2023 VS 2030

Figure 40. Europe Recombinant Hirudin Sales Value, (2019-2030) & (US$ Million)

Figure 41. Europe Recombinant Hirudin Sales Value by Type (%), 2023 VS 2030

Figure 42. Europe Recombinant Hirudin Sales Value by Application (%), 2023 VS 2030

Figure 43. China Recombinant Hirudin Sales Value, (2019-2030) & (US$ Million)

Figure 44. China Recombinant Hirudin Sales Value by Type (%), 2023 VS 2030

Figure 45. China Recombinant Hirudin Sales Value by Application (%), 2023 VS 2030

Figure 46. Japan Recombinant Hirudin Sales Value, (2019-2030) & (US$ Million)

Figure 47. Japan Recombinant Hirudin Sales Value by Type (%), 2023 VS 2030

Figure 48. Japan Recombinant Hirudin Sales Value by Application (%), 2023 VS 2030

Figure 49. South Korea Recombinant Hirudin Sales Value, (2019-2030) & (US$ Million)

Figure 50. South Korea Recombinant Hirudin Sales Value by Type (%), 2023 VS 2030

Figure 51. South Korea Recombinant Hirudin Sales Value by Application (%), 2023 VS 2030

Figure 52. Southeast Asia Recombinant Hirudin Sales Value, (2019-2030) & (US$ Million)

Figure 53. Southeast Asia Recombinant Hirudin Sales Value by Type (%), 2023 VS 2030

Figure 54. Southeast Asia Recombinant Hirudin Sales Value by Application (%), 2023 VS 2030

Figure 55. India Recombinant Hirudin Sales Value, (2019-2030) & (US$ Million)

Figure 56. India Recombinant Hirudin Sales Value by Type (%), 2023 VS 2030

Figure 57. India Recombinant Hirudin Sales Value by Application (%), 2023 VS 2030

Figure 58. Recombinant Hirudin Industrial Chain

Figure 59. Recombinant Hirudin Manufacturing Cost Structure

Figure 60. Channels of Distribution (Direct Sales, and Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions